No Data
Announcement of a research paper presentation by Kumamoto University – Regulation of the pathogenesis of synucleinopathy such as Parkinson's disease by 5-ALA.
SBI Pharma Co., Ltd., a subsidiary of SBI Holdings Co., Ltd., is conducting research and development of pharmaceuticals using 5-aminolevulinic acid (5-ALA) (※1) in November 27, 2024. Based in Minato-ku, Tokyo, the company is led by President and CEO Yoshitaka Kitao. SBI Pharma collaborates with the research group of Professor Michifumi Shioda, Associate Professor Koji Yabuki, and Assistant Professor Kazuya Matsuo from the National University Corporation Kumamoto University Institute of Health Science (referred to as the Kumamoto University research group).
Japan's SBI Follows Nomura in Disclosing Adani Funds Exposure
Announcement regarding the additional acquisition of shares in Mynavi Corporation and the application of equity method accounting.
On November 25, 2024, SBI Holdings Co., Ltd., we have entered into a capital and business alliance agreement with Mynavi Co., Ltd. (Headquarters: Chiyoda-ku, Tokyo, President and CEO: Yoshiaki Tsuchiya, hereinafter referred to as "Mynavi") in November 2023. However, this time, we have received additional shares from existing shareholders of Mynavi and will make the company an affiliate accounted for under the equity method of our company, so we would like to inform you. The voting rights ratio of the SBI Group to Mynavi is already held by our company.
Insider decrases its stake in SBI Holdings(8473.JP) to 6.31%
On Nov 21, ベイリー・ギフォード・アンド・カンパニー and related parties submitted the Change Report to Ministry of Finance. The report shows that ベイリー・ギフォード・アンド・カンパニー and related parties decreased their
Plug and Play Announces Expansion Into Seattle Along With Partnership With SBI Holdings and SNBL and Future Participation as Co-GP in SBI US Gateway Fund
SBI Partners With Saudi Entities to Launch Biotechnology Fund
No Data
No Data